We are live on ! Find out more
ISEE

IVERIC bio

Delisted

ISEE was delisted on the 10th of July, 2023.

162 hedge funds and large institutions have $2.02B invested in IVERIC bio in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

591% more call options, than puts

Call options by funds: $40.2M | Put options by funds: $5.82M

50% more funds holding in top 10

Funds holding in top 10: 8 → 12 (+4)

9% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 57

10% less capital inflows, than outflows

Capital inflows: $207M | Capital outflows: $229M

1.08% less ownership

Funds ownership: 104.83% → 103.75% (-1.1%)

7% less funds holding

Funds holding: 175 → 162 (-13)

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
162
Holders Change
-13
Holders Change %
-7.43%
% of All Funds
2.55%
Holding in Top 10
12
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+50%
% of All Funds
0.19%
New
19
Increased
62
Reduced
57
Closed
31
Calls
$40.2​M
Puts
$5.82​M
Net Calls
+$34.4​M
Net Calls Change
+$20.4​M

ISEE Hedge Fund Activity: Q1 2022 in Review

162 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio (ISEE) for Q1 2022, worth a combined $2.02B — up 0.79% from $2B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of ISEE and 19 opened new positions — a net loss of 12 holders — while 57 trimmed existing stakes and 62 added.

The largest buyer was Morgan Stanley, adding an estimated $31.9M. The largest seller was RTW Investments, exiting entirely with an estimated $112M sold.

  • 162 institutional investors held IVERIC bio (ISEE) as of Q1 2022, down from 175 in Q4 2021.
  • Funds reported $2.02B of IVERIC bio stock for Q1 2022, up 0.79% quarter-over-quarter.
  • 19 funds opened new IVERIC bio positions in Q1 2022 and 31 closed out, a net change of -12 holders.
  • The largest IVERIC bio buyer in Q1 2022 was Morgan Stanley, an estimated $31.9M added.
  • The largest IVERIC bio seller in Q1 2022 was RTW Investments, an estimated $112M sold.

Based on aggregated 13F filings for Q1 2022.